Westphal, Sören
Gantert, Thomas
Kless, Caroline
Hüttinger, Kristina
Klingenspor, Martin
Fromme, Tobias http://orcid.org/0000-0001-9150-2513
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FR 3628/2-1, FR 3628/2-1, FR 3628/2-1, FR 3628/2-1, FR 3628/2-1)
Article History
Received: 10 February 2019
Accepted: 20 May 2019
First Online: 11 June 2019
Competing Interests
: S.W., M.K. and T.F. are inventors and beneficiaries of a patent held by Technical University of Munich covering the use of FGF8 to treat metabolic disease (WO2015121457A1). Beyond, all authors declare the absence of competing interest.